The International Vitreoretinal B-Cell Lymphoma Registry: a protocol paper

dc.creatorJustine R. Smith
dc.creatorValérie Touitou
dc.creatorDaniel Vítor de Vasconcelos Santos
dc.creatorDavid J. Wilson
dc.creatorSteven Yeh
dc.creatorMark H. B. Radford
dc.creatorAlexandra L. Farrall
dc.creatorJanet L. Davis
dc.creatorJoke H. de Boer
dc.creatorAnthony J. Hall
dc.creatorManabu Mochizuki
dc.creatorH. Nida Sen
dc.creatorHiroshi Takase
dc.creatorNinette H. Ten Dam-van Loon
dc.date.accessioned2023-12-05T20:35:33Z
dc.date.accessioned2025-09-09T00:01:13Z
dc.date.available2023-12-05T20:35:33Z
dc.date.issued2022
dc.format.mimetypepdf
dc.identifier.doihttps://doi.org/10.1136/bmjopen-2021-060701
dc.identifier.issn2044-6055
dc.identifier.urihttps://hdl.handle.net/1843/61743
dc.languageeng
dc.publisherUniversidade Federal de Minas Gerais
dc.relation.ispartofBMJ Open
dc.rightsAcesso Aberto
dc.subjectGuias como Assunto
dc.subjectLinfoma
dc.subjectNeoplasias
dc.subject.otherGuias como Assunto
dc.subject.otherLinfoma
dc.subject.otherNeoplasias
dc.titleThe International Vitreoretinal B-Cell Lymphoma Registry: a protocol paper
dc.typeArtigo de periódico
local.citation.epage6
local.citation.issue7
local.citation.spagee060701
local.citation.volume12
local.description.resumoIntroduction Vitreoretinal lymphoma is a rare ocular cancer with high morbidity and mortality despite treatment. Diagnosis by cytopathology is often delayed, and various molecular and image-based investigations have been developed. Diverse treatments are used, but there is a limited medical evidence to differentiate their effectiveness. We designed an international registry that would collect diagnostic, treatment and outcomes data, to establish new evidence for the management of this cancer. Methods and analysis The International Vitreoretinal B-Cell Lymphoma Registry will accrue data retrospectively for individuals aged 18 years or older, diagnosed with new or recurrent vitreoretinal B-cell lymphoma on or after 1 January 2020. A steering committee of subspecialised ophthalmologists identified 20 key clinical data items that describe patient demographics, tissue involvements, diagnostic testing, ocular and systemic treatments and treatment complications, and visual acuity and survival outcomes. Customised software was designed to permit collection of these data across a single baseline and multiple follow-up forms. The platform collects data without identifiers and at 3 month reporting intervals. Outcomes of the project will include: (1) descriptions of clinical presentations, and diagnostic and therapeutic preferences; (2) associations between clinical presentations, and diagnostics and treatments, and between diagnostics and treatments (assessed by ORs with 95% CIs); and (3) estimations of rates of vision loss, and progression-free and overall survival (assessed by Kaplan-Meier estimates). Ethics and dissemination The registry has received Australia-wide approval by a national human research ethics committee. Sites located outside Australia are required to seek local human research ethics review. Results generated through the registry will be disseminated primarily by peer-reviewed publications that are expected to inform clinical practice, as well as educational materials.
local.identifier.orcidhttp://orcid.org/0000-0002-4756-5493
local.identifier.orcidhttp://orcid.org/0000-0002-0909-8978
local.identifier.orcidhttps://orcid.org/0000-0002-6747-2024
local.publisher.countryBrasil
local.publisher.departmentMED - DEPARTAMENTO DE OFTALMOLOGIA E OTORRINOLARINGOLOGIA
local.publisher.departmentMEDICINA - FACULDADE DE MEDICINA
local.publisher.initialsUFMG
local.url.externahttps://bmjopen.bmj.com/content/12/7/e060701

Arquivos

Pacote original

Agora exibindo 1 - 1 de 1
Carregando...
Imagem de Miniatura
Nome:
The International Vitreoretinal B-Cell Lymphoma Registry_ a protocol paper.pdf
Tamanho:
161.63 KB
Formato:
Adobe Portable Document Format

Licença do pacote

Agora exibindo 1 - 1 de 1
Carregando...
Imagem de Miniatura
Nome:
License.txt
Tamanho:
1.99 KB
Formato:
Plain Text
Descrição: